Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

4724 ARTÍCULOS , VIENDO DEL 901 AL 915

Validations of apomorphine-induced BOLD activation correlations in hemiparkinsonian rhesus macaques

Quintero JE, Ai Y, Andersen AH, Hardy P, Grondin R, Guduru Z, Gash DM, Gerhardt GA, Zhang Z.

Neuroimage Clin. 2019;22:101724. doi: 10.1016/j.nicl.2019.101724. Epub 2019 Feb 18.

High-Pressure Response of Amyloid Folds

Torrent J, Martin D, Igel-Egalon A, Béringue V, Rezaei H.

Viruses. 2019 Feb 28;11(3):202. doi: 10.3390/v11030202.

Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors

Stansley BJ, Conn PJ.

Trends Pharmacol Sci. 2019 Apr;40(4):240-252. doi: 10.1016/j.tips.2019.02.006. Epub 2019 Feb 26.

Creativity related to dopaminergic treatment: A multicenter study

Garcia-Ruiz PJ, Martinez Castrillo JC, Desojo LV.

Parkinsonism Relat Disord. 2019 Jun;63:169-173. doi: 10.1016/j.parkreldis.2019.02.010. Epub 2019 Feb 22.

Neuroleptic malignant syndrome as part of an akinetic crisis associated with sepsis in a patient with Lewy body disease

Manabe S, Yanagi H, Ozawa H, Takagi A.

BMJ Case Rep. 2019 Feb 28;12(2):e227216. doi: 10.1136/bcr-2018-227216.

Increased dose of carbidopa with levodopa and entacapone improves "off" time in a randomized trial

Trenkwalder C, Kuoppamäki M, Vahteristo M, Müller T, Ellmén J.

Neurology. 2019 Mar 26;92(13):e1487-e1496. doi: 10.1212/WNL.0000000000007173. Epub 2019 Mar 1.

Managing treatment fluctuations in Parkinson disease: "On" again-, "off" again

Metzer WS, Rodrigues FB.

Neurology. 2019 Mar 26;92(13):597-598. doi: 10.1212/WNL.0000000000007193. Epub 2019 Mar 1.

Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease

Ztaou S, Amalric M.

Neurochem Int. 2019 Jun;126:1-10. doi: 10.1016/j.neuint.2019.02.019. Epub 2019 Feb 27.

Upper limb motor pre-clinical assessment in Parkinson's disease using machine learning

Cavallo F, Moschetti A, Esposito D, Maremmani C, Rovini E.

Parkinsonism Relat Disord. 2019 Jun;63:111-116. doi: 10.1016/j.parkreldis.2019.02.028. Epub 2019 Feb 22.

Asymmetric STN DBS for FOG in Parkinson's disease: A pilot trial

Meoni S, Debȗ B, Pelissier P, Scelzo E, Castrioto A, Seigneuret E, Chabardes S, Fraix V, Moro E.

Parkinsonism Relat Disord. 2019 Jun;63:94-99. doi: 10.1016/j.parkreldis.2019.02.032. Epub 2019 Feb 25.

Harnessing Stem Cells and Neurotrophic Factors with Novel Technologies in the Treatment of Parkinson's Disease

Conese M, Cassano R, Gavini E, Trapani G, Rassu G, Sanna E, Di Gioia S, Trapani A.

Curr Stem Cell Res Ther. 2019;14(7):549-569. doi: 10.2174/1574888X14666190301150210.

The centromedian nucleus: Anatomy, physiology, and clinical implications

Ilyas A, Pizarro D, Romeo AK, Riley KO, Pati S.

J Clin Neurosci. 2019 May;63:1-7. doi: 10.1016/j.jocn.2019.01.050. Epub 2019 Feb 28.

T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease

Campos-Acuña J, Elgueta D, Pacheco R.

Front Immunol. 2019 Feb 15;10:239. doi: 10.3389/fimmu.2019.00239. eCollection 2019.

[Guideline-conform exact diagnosis and coding of dementia]

Hofmann W, Wille E, Kaminsky S.

Z Gerontol Geriatr. 2019 Mar;52(2):179-194. doi: 10.1007/s00391-019-01509-3. Epub 2019 Mar 4.

Significant roles of neuroinflammation in Parkinson's disease: therapeutic targets for PD prevention

Lee Y, Lee S, Chang SC, Lee J.

Arch Pharm Res. 2019 May;42(5):416-425. doi: 10.1007/s12272-019-01133-0. Epub 2019 Mar 4.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias